Sangamo Therapeutics (NASDAQ:SGMO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 [Yahoo! Finance]
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by analysts at
Wall St